Pfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid decline

Pfizer Inc. (NYSE: PFE) has announced its financial outcomes for the first quarter of 2024, displaying strong performance in its non-COVID product portfolio. This includes heightened revenues from recent commercial launches and acquired products, alongside a consistent growth in key in-line brands. Despite a decrease in pandemic-related revenues, the company has raised its Adjusted diluted […]